Vinpocetine
Ethyl apovincaminate · Cavinton · Intelectol · TCV-3B · RGH-4405
Last updated
At a glance
Overview
Why Vinpocetine Earned Its Place in the Stack#
Vinpocetine is one of the older, better-characterized nootropics in the catalog — a semi-synthetic Vinca minor derivative that has been clinically prescribed in Hungary, Germany, Japan, and Russia as Cavinton for cerebrovascular insufficiency since the 1970s. The community reaches for it for a specific reason: it's the cleanest available PDE1 inhibitor and cerebral vasodilator, raising regional blood flow and glucose delivery in hypoperfused tissue without behaving like a stimulant. Users running racetam stacks pair it with piracetam and a choline source as the "vascular layer" of the protocol. Tinnitus and sudden sensorineural hearing loss experimenters use it for cochlear microcirculation. Physique-focused users on heavy cycles add 20–30mg/day as cheap cerebrovascular insurance against the hematocrit and blood-pressure load of on-cycle life.
The mechanism stack is unusually well-mapped for a grey-market nootropic: selective PDE1 inhibition raises cGMP in cerebral vascular smooth muscle, voltage-gated Na⁺ channel blockade delivers the neuroprotective signal in ischemic / excitotoxic settings, and an independent IKK / NF-κB inhibition pathway suppresses TNF-α and IL-1β in microglia and endothelium.
"Vinpocetine directly inhibited IKK activity in vitro and suppressed LPS-induced TNF-α, IL-1β, and ICAM-1 expression in primary microglia and endothelial cells." — Jeon et al., PNAS (2010)
The sections below cover documented vinpocetine dosage ranges (5–60mg/day, divided with meals), the canonical racetam-and-choline stack, use-case protocols for focus, tinnitus, and on-cycle vascular support, the side-effect profile, and the one hard contraindication — pregnancy and pregnancy potential — that is not negotiable.
How Vinpocetine works
Vinpocetine is a semi-synthetic derivative of vincamine, the principal alkaloid of Vinca minor. Its mechanism is unusually clean for a nootropic: three reasonably well-characterized molecular actions converge on a single practical outcome — improved perfusion, metabolism, and resilience of brain tissue, particularly where blood flow is already compromised.
Selective PDE1 Inhibition and Cerebral Vasodilation#
The headline mechanism is selective inhibition of Ca²⁺/calmodulin-dependent phosphodiesterase 1 (PDE1). PDE1 normally degrades cGMP and cAMP in vascular smooth muscle. By blocking it, vinpocetine raises intracellular cGMP, relaxes cerebral arteriolar smooth muscle, and increases regional cerebral blood flow without producing meaningful systemic vasodilation. This selectivity is why subjects rarely report the flushing or systemic blood-pressure drops seen with non-selective vasodilators, while still showing measurable increases in cerebral perfusion on imaging.
The practical translation: more oxygen and glucose delivered to working cortical tissue. This is the mechanism the nootropic community is paying for — the "haze lifting" effect described in stacks alongside racetams, where piracetam increases cerebral metabolic demand and vinpocetine increases the supply side to match.
Voltage-Gated Sodium Channel Blockade#
Independent of the PDE1 pathway, vinpocetine inhibits neuronal voltage-gated Na⁺ channels. This blunts the depolarization cascade that, under hypoxic or excitotoxic conditions, drives pathological Ca²⁺ influx and downstream neuronal injury. It is the dominant neuroprotective mechanism in stroke, hypoxia, and TBI models.
"Our results indicate that the neuroprotective effect of vinpocetine is at least partly attributable to inhibition of sodium channel activity." — Bönöczk P, Gulyás B, Adam-Vizi V, et al. Brain Research Bulletin, 2000
For physique-focused users, the relevant context is on-cycle vascular load: elevated hematocrit, blood viscosity, and systemic pressure on heavy AAS protocols translate to a more strained cerebrovascular bed. The Na⁺-channel mechanism is positioned in PED circles as cheap insurance against the kind of microvascular insults that accumulate silently over years of cycling.
NF-κB / IKK Inhibition and Anti-Inflammatory Signalling#
A third mechanism, characterized more recently, is direct inhibition of IKK (the kinase that activates NF-κB), independent of PDE1. This suppresses transcription of TNF-α, IL-1β, and adhesion molecules like ICAM-1 in microglia and vascular endothelium.
"Vinpocetine directly inhibited IKK activity in vitro and suppressed LPS-induced TNF-α, IL-1β, and ICAM-1 expression in primary microglia and endothelial cells." — Jeon KI, Xu X, Aizawa T, et al. Proceedings of the National Academy of Sciences, 2010
Practically, this is the mechanism underwriting the use of vinpocetine in tinnitus, sudden sensorineural hearing loss, and post-TBI recovery protocols — settings where cochlear or cerebral microvascular inflammation is part of the pathology rather than just hypoperfusion alone.
Hemorheological Effects#
Vinpocetine also improves erythrocyte deformability and modestly reduces platelet aggregation. Red cells that bend more easily move through capillaries with less resistance, which compounds the macroscopic vasodilatory effect at the microcirculation level. The anti-aggregant action is mild but real, and is the reason vinpocetine stacks awkwardly with aspirin, fish oil at high doses, NSAIDs, and PDE5 inhibitors — additive effects on bleeding time become relevant before, say, dental procedures or surgery.
For the looksmaxxing subset experimenting with scalp microcirculation stacks (oral minoxidil, daily low-dose tadalafil), the hemorheological mechanism is the inferential basis for adding vinpocetine — anything that improves microvascular flow is theoretically additive, though direct evidence in hair endpoints is absent.
Pharmacokinetic Translation to Dosing#
The mechanisms above are clean; the pharmacokinetics are what determine whether a protocol actually delivers them.
"Oral bioavailability averaged 56.6 ± 8.9% under fasting conditions, with plasma concentration peaks 1–1.5 h post-dose and a biphasic elimination half-life profile." — Vereczkey L, Czira G, Karvaly G, et al. Arzneimittel-Forschung, 1979
Two facts dominate the protocol:
| PK Variable | Value | Practical Consequence |
|---|---|---|
| Parent half-life | ~1–2 h | Single AM dosing leaves most of the day uncovered |
| Food effect on AUC | ~1.6–2.0× | Fasted dosing wastes roughly half the dose |
| Tmax | 1–1.5 h | Pre-work timing is straightforward |
| Active metabolite (AVA) | ~5 h terminal | Extends the functional window past parent clearance |
This is why standard protocols are divided three times daily with meals rather than a single morning dose, and why bulk-powder users who dry-dose on an empty stomach consistently underperform capsule users at the same nominal mg/day.
Net Effect#
Stack the four mechanisms and the picture is coherent: a compound that selectively raises cerebral perfusion, protects neurons from ischemic and excitotoxic insult, dampens vascular and microglial inflammation, and improves microcirculatory rheology — all without androgen, estrogen, or HPTA activity, and without meaningful effect on systemic blood pressure at standard doses. The signal is strongest in hypoperfused or inflamed tissue (post-TBI, tinnitus, cerebrovascular insufficiency, on-cycle vascular strain), which is also why healthy young subjects with already-optimal cerebral flow report subtler effects than the older clinical literature might suggest. Match the mechanism to the use-case and vinpocetine earns its slot in the stack.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 5–10 mg | 3× daily | Documented entry-level range |
| Mid | 20–30 mg | 3× daily | Most commonly studied range |
| High | 45–60 mg | 3× daily | Divided dosing with meals materially outperforms single AM dosing because parent half-life is short and food roughly doubles bioavailability. Standard protocol is 10mg three times daily with breakfast, lunch, and an afternoon meal. Avoid late-evening dosing to prevent sleep disturbance. |
Cycle length & outcomes
Documented cycle
4–12 weeks
Plateau after
12 wks
Cycle Notes#
Vinpocetine doesn't behave like an anabolic or a peptide — there's no receptor downregulation to chase, no HPTA to recover, and no loading phase to slog through. The compound works on cerebral vasculature and PDE1 from the first dose, but cognitive endpoints lag the pharmacology by 2–4 weeks. Acute single-dose effects are real but subtle; the meaningful gains show up on chronic divided dosing with meals.
Cycle Length by Goal#
| Goal | Cycle Length | Daily Dose | Schedule |
|---|---|---|---|
| Acute pre-work focus | Single dose, as needed | 10–20mg | 30–45 min before task, with fat-containing snack |
| Racetam stack adjunct | 8–12 weeks | 20–30mg | 10mg with breakfast, lunch, afternoon meal |
| Tinnitus / sudden hearing loss | 8–12 weeks | 30mg | 10mg × 3 with meals |
| On-cycle cerebrovascular support | Run alongside AAS cycle | 20mg | 10mg × 2 with meals |
| Post-concussion / TBI recovery | 8–12 weeks | 30mg | 10mg × 3 with meals |
| Aggressive nootropic protocol | 8–12 weeks | 45–60mg | 15–20mg × 3 with meals |
Dosing Schedule#
The parent half-life is roughly 1–2 hours, with the active metabolite apovincaminic acid carrying the tail. This makes divided dosing non-negotiable for chronic protocols — a single 30mg morning dose leaves the afternoon and evening uncovered, while 10mg three times daily holds a steady cerebral perfusion floor.
Food is the second non-negotiable variable. Fasted bioavailability is ~57%, and a fat-containing meal roughly doubles AUC:
"Oral bioavailability averaged 56.6 ± 8.9% under fasting conditions, with plasma concentration peaks 1–1.5 h post-dose and a biphasic elimination half-life profile." — Vereczkey et al., Arzneimittel-Forschung (1979)
Practical translation: every dose is administered with a meal containing some fat. Empty-stomach dosing wastes roughly half the compound. Late-evening administration is avoided to prevent sleep disruption — the third dose lands with an afternoon meal, not dinner.
Onset and Expectations#
Acute effects (single dose): mild cerebral "openness," reduced mental haze, subtle improvement in word retrieval and focus, peaking 1–1.5 hours post-dose and tapering by hour 3. Users expecting stimulant-like clarity will be disappointed — the signal is vascular, not dopaminergic.
Chronic effects (2–4 weeks of consistent dosing): the cognitive endpoints documented in the Cavinton trials — working memory, attention, processing speed in hypoperfused subjects — show up here. Healthy young users see a more modest signal than aging or post-TBI subjects, which is consistent with the mechanism: vinpocetine does the most work in tissue that is underperfused to begin with.
Tinnitus and hearing protocols typically need the full 8–12 weeks before assessment:
"Vinpocetine was associated with statistically significant improvements in hearing outcomes in patients with sudden sensorineural hearing loss." — Konopka et al., Otolaryngologia Polska (2014)
Loading, Tapering, and Cycling#
No loading phase is required or beneficial. Starting at 10mg × 3 with meals from day one is the standard approach. Some users ramp from 5mg × 2 for the first week if they're sensitive to vasodilators (headache, flushing) — this is a tolerance smoothing measure, not a pharmacological necessity.
No taper is required. Vinpocetine doesn't suppress endogenous anything, doesn't produce dependence, and has no documented withdrawal syndrome. Discontinuation is abrupt without consequence.
Cycling rationale is weak. No clear tolerance mechanism has been characterized in the literature, and Eastern European clinical practice routinely runs continuous protocols of 90+ days. The community convention of 8–12 weeks on, 2–4 weeks off is precautionary rather than evidence-based — chronic dosing past 12 weeks appears safe, and the dose-response curve plateaus rather than degrades. Users running tinnitus or post-TBI protocols often continue past 12 weeks without issue.
Bloodwork Cadence#
Vinpocetine is not a high-monitoring compound. For protocols under 30mg/day at standard cycle lengths, no specific bloodwork is required. For aggressive protocols (45–60mg/day) run beyond 12 weeks, the sensible panel at the 90-day mark includes:
- CBC — platelet count for context, given the mild anti-aggregant effect
- CMP / LFTs — modest transaminase elevations have been reported on long-term high-dose protocols, though they are rare
- Blood pressure log — relevant for users stacking with tadalafil, telmisartan, or running it alongside AAS BP-management protocols
Users running vinpocetine inside an AAS cycle should rely on the cycle's standard bloodwork cadence (lipids, hematocrit, eGFR, LFTs at 6 and 12 weeks) — vinpocetine doesn't add new monitoring requirements but is comfortably tracked inside the existing panel.
Stacking Notes Inside the Cycle#
The canonical chronic protocol is piracetam 1.6–3.2g + alpha-GPC 300mg + vinpocetine 10mg, three times daily with meals. The racetam drives metabolic demand, alpha-GPC supplies the acetylcholine substrate, and vinpocetine handles cerebral perfusion and glucose delivery. This is the stack the older nootropic literature is built around and remains the default starting point.
For looksmaxxing-adjacent use cases — hair stack microcirculation experimenters, on-cycle BP management, daily tadalafil users — vinpocetine sits comfortably alongside tadalafil 2.5–5mg, telmisartan, and citrulline, with the caveat that additive hypotension is possible at the top of the dose range. Starting at 10mg × 2 and titrating up is the sensible approach when stacking multiple vasodilators.
Run cleanly with meals, divided three times daily, for at least 4 weeks before judging the protocol. Most users who report "vinpocetine didn't do anything" were dosing 30mg once in the morning on an empty stomach for a week — which is roughly the worst possible execution of an otherwise well-characterized compound.
Risks & mistakes
Common (most users)#
- Headache — paradoxical given the vasodilatory mechanism, usually appears in the first week and resolves on its own. Drop the divided dose by half (5mg per administration) for a few days, then titrate back up. Adequate hydration and consistent food pairing materially reduce incidence.
- Mild hypotension / lightheadedness on standing — most common at the upper end of the dose range or when stacked with other vasodilators (tadalafil, citrulline, telmisartan). Slowing positional changes and dosing with a salted meal handles it.
- Flushing, transient tachycardia — vascular signature, benign, fades with continued administration. No mitigation required beyond patience.
- GI upset / nausea — almost entirely solved by administering with a fat-containing meal, which is the recommended protocol anyway. Vereczkey 1979 documented that food roughly doubles AUC, so this single change improves both tolerance and effect.
- Sleep disturbance with late dosing — the third daily dose belongs at the afternoon meal, not the evening one. Cerebral perfusion effects plus the short parent half-life make late administration counterproductive for sleep onset.
Uncommon (dose-dependent or individual)#
- Dry mouth, transient rash — uncommon, generally cosmetic. If rash persists past a few days, the protocol is discontinued.
- Modest transaminase elevations — reported rarely on long-term protocols >30mg/day. An LFT panel at the 90-day mark is sensible for anyone running the advanced dose range chronically.
- Additive hypotension with PDE5 inhibitors or antihypertensives — relevant for users running daily tadalafil on cycle alongside telmisartan or similar. Symptomatic dizziness is the cue to drop vinpocetine to the low-intermediate range.
- Increased bleeding tendency — vinpocetine reduces platelet aggregation. Bruising more easily, slow-clotting cuts, or heavier nosebleeds are signs the antiplatelet load (vinpocetine + fish oil + aspirin + AAS-driven hematocrit shifts) is stacking too high. Pull one of the antiplatelet inputs.
Rare but serious#
- Hemorrhagic events — the antiplatelet effect is real but mild at standard doses. The serious-event signal lives in stacks: vinpocetine plus warfarin, clopidogrel, high-dose aspirin, or active NSAID use. Warning signs are unusual bruising, blood in stool or urine, persistent epistaxis, or unexplained headache with neurological symptoms. Discontinue immediately and seek evaluation.
- Severe hypotensive episode — rare, generally requires stacking with multiple vasodilators or pre-existing low baseline BP. Syncope is the unambiguous stop signal.
- Idiosyncratic hepatotoxicity — vanishingly rare in the literature but worth flagging for users on long, high-dose protocols. RUQ pain, jaundice, dark urine, persistent nausea → discontinue and pull bloods.
"Vinpocetine demonstrated in vitro inhibition of CYP2D6, but the likelihood of clinically meaningful drug interactions at normal doses appears low." — Manda et al., Medicines (2015)
CYP2D6 inhibition is in vitro and unlikely to matter at 15–30mg/day, but stacks built around heavy CYP2D6 substrates (tramadol, certain SSRIs, beta-blockers) warrant attention at the 45–60mg/day end.
Hard contraindications#
- Pregnancy or pregnancy potential. This is absolute. NTP rat and rabbit studies showed decreased fetal weight and increased embryofetal mortality at exposures comparable to a single human dose, and the FDA in 2019 issued an explicit warning to women of childbearing age. Vinpocetine is not run by anyone who is pregnant, could become pregnant, or is actively trying to conceive.
- Active bleeding or recent hemorrhagic stroke. The antiplatelet effect makes this a non-starter.
- Concurrent therapeutic anticoagulation (warfarin, DOACs, therapeutic-dose heparins). Additive bleeding risk without a meaningful upside.
- Severe baseline hypotension. The vasodilatory mechanism is the wrong tool.
- Organ transplant immunosuppression. Vinpocetine's NF-κB / IKK inhibition has a plausible interaction surface with calcineurin inhibitors. Data is thin; conservative practice avoids the stack entirely.
- Scheduled surgical or dental procedures within 7–10 days. Discontinue in advance to normalize platelet function.
"In both rats and rabbits, vinpocetine induced decreased fetal weight and increased incidence of embryofetal mortality at exposures similar to a single human dose." — Catlin et al., Birth Defects Research (2018)
Gender-specific and PCT considerations#
Vinpocetine has no androgen-receptor, estrogen-receptor, or HPTA activity. It does not suppress endogenous testosterone, does not aromatize, does not require any ancillary, and runs cleanly alongside SARM and AAS cycles or through PCT without endocrine concern. Dosing is not bodyweight-scaled and is identical across the subject pool outside of the pregnancy contraindication.
The teratogenicity signal is the dominant gender-specific consideration and it is non-negotiable: reproductive-age female subjects do not run vinpocetine, full stop. For everyone else, the side-effect profile is benign, the failure modes are mostly stack-design problems (too many antiplatelets, too many vasodilators, late-evening dosing), and the compound earns its place in a nootropic or on-cycle vascular stack with very little to manage.
FAQ — Vinpocetine
Research & citations
6 studies cited on this page.
Conclusion
Vinpocetine is a go-to vascular-support nootropic for researchers looking to enhance cerebral blood flow, support cognitive recovery, or round out a classic racetam stack. Its safety profile is clean outside hard pregnancy contraindications, and it fits naturally as the 'cerebral perfusion' layer rather than a headline stim.
Key takeaways:
- Standard protocol: 10 mg orally, three times daily with meals (total 30 mg/day) — divided dosing with food is critical for bioavailability (Vereczkey et al., 1979)
- Dosing range: 5–10 mg for beginners, 20–30 mg standard, up to 45–60 mg/day in aggressive stacks
- Cycle duration: 4–12 weeks continuous; most run 8–12 weeks on, 2–4 weeks off
- Canonical stack: piracetam (or other racetam) + choline (alpha-GPC/CDP) + vinpocetine improves cerebral energy delivery and focus
- Main benefit: increased cerebral perfusion, neuroprotection, and evidence-backed support for tinnitus or acute hearing loss (Konopka et al., 2014)
- Absolute contraindication in pregnancy and pregnancy potential — do not include in protocols involving women of childbearing potential (Catlin et al., 2018; FDA, 2019)
For cognitive enhancement, racetam stacking, or hearing-support protocols, vinpocetine is one of the best-characterized, low-risk tools on the research market.